Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives $15.60 Average Target Price from Brokerages

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have received an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $15.60.

KLRS has been the subject of several research reports. Wall Street Zen lowered Kalaris Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, June 14th. Citizens Jmp cut their price target on Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Morgan Stanley began coverage on Kalaris Therapeutics in a report on Thursday, April 16th. They issued an “overweight” rating and a $14.00 price objective for the company. Weiss Ratings upgraded Kalaris Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 7th. Finally, TD Cowen initiated coverage on shares of Kalaris Therapeutics in a report on Monday, June 15th. They set a “buy” rating on the stock.

Kalaris Therapeutics Stock Performance

NASDAQ KLRS opened at $4.55 on Friday. The company has a market capitalization of $108.24 million, a PE ratio of -2.12 and a beta of 0.19. Kalaris Therapeutics has a 52-week low of $2.14 and a 52-week high of $11.88. The company has a 50-day simple moving average of $4.67 and a 200 day simple moving average of $6.94.

Kalaris Therapeutics (NASDAQ:KLRS) last released its earnings results on Tuesday, May 12th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.06. As a group, analysts forecast that Kalaris Therapeutics will post -2 EPS for the current fiscal year.

Insider Buying and Selling at Kalaris Therapeutics

In other Kalaris Therapeutics news, Director Srinivas Akkaraju purchased 244,300 shares of the stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $4.83 per share, with a total value of $1,179,969.00. Following the completion of the transaction, the director directly owned 2,224,147 shares in the company, valued at approximately $10,742,630.01. This trade represents a 12.34% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 68.10% of the stock is owned by insiders.

Institutional Trading of Kalaris Therapeutics

A number of institutional investors have recently modified their holdings of KLRS. XTX Topco Ltd bought a new position in shares of Kalaris Therapeutics in the second quarter worth $65,000. Johnson Financial Group Inc. purchased a new stake in shares of Kalaris Therapeutics in the third quarter worth about $58,000. Bridgeway Capital Management LLC bought a new position in shares of Kalaris Therapeutics in the third quarter valued at approximately $130,000. Woodline Partners LP bought a new position in shares of Kalaris Therapeutics in the third quarter valued at approximately $1,394,000. Finally, WHI TRUST Co LLC bought a new position in shares of Kalaris Therapeutics in the fourth quarter valued at approximately $823,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.